HHLR Advisors’s Pyxis Oncology PYXS Stock Holding History

HHLR Advisors’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-382,606	Closed	-$597K	–	54
2024 Q4	$597K	Hold	382,606	–	–	0.02%	41
2024 Q3	$1.4M	Hold	382,606	–	–	0.03%	39
2024 Q2	$1.27M	Hold	382,606	–	–	0.03%	67
2024 Q1	$1.63M	Hold	382,606	–	–	0.04%	53
2023 Q4	$689K	Hold	382,606	–	–	0.01%	45
2023 Q3	$761K	Hold	382,606	–	–	0.02%	53
2023 Q2	$979K	Sell	382,606 -148,086	-28%	-$470K	0.02%	54
2023 Q1	$2.13M	Sell	530,692 -233,714	-31%	-$467K	0.04%	60
2022 Q4	$1.02M	Hold	764,406	–	–	0.02%	62
2022 Q3	$1.51M	Hold	764,406	–	–	0.04%	56
2022 Q2	$1.82M	Hold	764,406	–	–	0.04%	59
2022 Q1	$3.09M	Hold	764,406	–	–	0.06%	53
2021 Q4	$8.39M	Buy	+764,406	New	+$8.75M	0.13%	53

Other funds holding PYXS

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

HHLR Advisors's PYXS Position: Q1 2025 in Review

HHLR Advisors sold out of Pyxis Oncology (PYXS) in Q1 2025, closing a stake of 382,606 shares — an estimated $597K sold.

HHLR Advisors first reported a position in PYXS in Q4 2021 and held it in 13 quarters. The position peaked at $8.39M in Q4 2021. 89 funds tracked by Wall St. Rank hold PYXS as of Q1 2025.

HHLR Advisors reported no remaining Pyxis Oncology position as of Q1 2025 after selling out during the quarter.
HHLR Advisors sold 382,606 Pyxis Oncology shares in Q1 2025, an estimated $597K.
HHLR Advisors first reported a position in Pyxis Oncology in Q4 2021 and held it in 13 quarters.
HHLR Advisors's Pyxis Oncology position peaked at $8.39M in Q4 2021.
89 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2025.

Based on HHLR Advisors's 13F filing for Q1 2025, filed 15 May 2025.